We thus emphasize the patient counseling evaluation study context and the intrinsically unblinded nature of this contrast, where usual care was familiar to participants. Lifestyle interventions in the primary care setting are widely recognized as

being important for public health purposes, so such studies must be as rigorous as possible [22]. A brief trial selleck monoclonal humanized antibody inhibitor description is provided below, with further details available elsewhere [21]. The CAMWEL trial evaluated the effectiveness of a structured one-to-one support program delivered in primary care over a 12 month period by trained advisors for overweight or obese people who wished to lose weight among residents of Camden, an ethnically diverse inner London borough with a mix of areas of relative affluence and deprivation. The trial participants were 381 adults with body mass index (BMI) ≥ 25 kg/m2 recruited in 23/39 National Health Service (NHS) Camden general practices between July 2009 and January 2010 [21]. The trial was AP24534 datasheet pragmatic in nature so as to be generalizable across the UK NHS, with as few exclusion criteria as possible [21]. Brief telephone screening was followed by a face-to-face appointment with a researcher for informed consent,

baseline questionnaire completion and anthropometric measures. Participants were randomly allocated to the patient counseling program being evaluated or to usual care, which is general practitioner management, potentially involving

prescription of weight loss drugs, referral to dieticians or for weight loss surgery [21]. Process studies are recommended within trials to confirm that the study is being implemented as intended and to explore intervention delivery issues, contextual factors and possible mechanisms linking processes to outcomes [23]. The CAMWEL process study collected semi-structured interview data from 34 (17 in each arm) of the 381 trial participants who were purposively selected to be diverse in gender, age, education and baseline weight. Participants provided separate consent to take part in the process study. The trial was approved by the London School of Hygiene & Tropical Medicine (LSHTM) Ethics Committee, the Camden and Islington Community Research Ethics Committee (REC Reference number 09/H0722/22), Farnesyltransferase and the North Central London Research Consortium. The purpose of this study is to explore to what extent participants’ reactions to being randomized, in the context of their decision to take part in the trial, inform understanding of the construct of performance bias. During the first process study interview, undertaken usually in the weeks following communication of the outcome of randomization by telephone, we investigated what impact the conduct of the trial had on 14 consecutive process study participants (8 control group, 6 intervention group).